Restoring what’s lost

Silencing what shouldn’t be

Arnatar is reimagining RNA medicines to precisely silence disease drivers or restore what’s missing. Through our dual-modality DARGER™ platform, we develop best-in-class siRNA and first-in-class upregulating ASOs for cardiometabolic, liver, CNS, and kidney diseases.

Our Platform

Rewriting the RNA playbook to 
transform lives

Founded by pioneers in RNA therapeutics, Arnatar is advancing a new era of programmable medicine.

Our mission is to deliver precision RNA therapies that go beyond gene silencing—restoring critical protein function and offering long-term disease control. With deep discovery expertise, differentiated delivery, and a commitment to translating innovation into impact, we aim to improve outcomes across diseases where current treatments fall short.

A dual-modality RNA engine

The DARGER™ platform uniquely combines gene silencing with the ability to upregulate protein expression using antisense oligonucleotides. Our siRNA technology delivers potent, durable downregulation, while ACT-UP1—our ASO-based upregulation engine—restores protein production through translation enhancement. Together, these capabilities unlock previously untreatable targets with precision, scalability, and safety, enabling a robust pipeline across cardiovascular, metabolic, CNS, and rare diseases.

Our Platform